HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support

Bone Marrow Transplantation

Volumn 27, Issue 8, 2001, Pages 847-853

  Bewick, M ^a   Conlon, M ^a   Gerard, S ^a   Lee, H ^a   Parissenti, A M ^a   Zhang, L ^a   Gluck S ^b   Lafrenie, R M ^a  

^a Northeastern Ontario Regional Cancer Centre   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

HER 2; High dose chemotherapy; Metastatic breast cancer; Paclitaxel; Plasma levels; Prognostic marker

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; MITOXANTRONE; PACLITAXEL; PROTEIN TYROSINE KINASE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; AUTOTRANSPLANTATION; BLOOD LEVEL; BREAST CANCER; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FEMALE; GENE EXPRESSION; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MULTIVARIATE ANALYSIS; ONCOGENE NEU; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; STEM CELL TRANSPLANTATION;

ADULT; AGED; ANALYSIS OF VARIANCE; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; RECEPTOR, ERBB-2; REMISSION INDUCTION; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0034986515     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703005     Document Type: Article

References (36)

1. HER-2/neu gene in human cancers
2. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
3. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
4. Elevated serum HER-2/neu level predicts decrease response to hormone therapy in metastatic breast cancer
5. A metanalysis of the interaction between Her2 and the response to endocrine therapy (ET) in metastatic breast cancer (MBC)
6. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor and target for therapy
7. Expression of C-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support
8. Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high dose chemotherapy and autologous stem cell transplantation
9. Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: A phase II study
10. High response rate with a lower dose of paclitaxel in combination with cisplatin in heavily pretreated patients with advanced breast carcinoma
11. Paclitaxel-containing high-dose chemotherapy in high-risk breast cancer patients
12. Docetaxel administered on a weekly basis for metastatic breast cancer
13. High-dose paclitaxel, cyclophosphamide and mitoxantrone followed by autologous blood stem cell support for the treatment of metastatic breast cancer: A phase I trial
14. Nonparametric estimation from incomplete observations
15. Regression models and life-tables (with discussion)
16. ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor negative breast cancer
17. C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer
18. Long term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer
19. Conventional dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem cell transplantation for metastatic breast cancer
20. Immunohistochemical and histopathologic factors predicting progression-free survival (PFS) and overall survival (OS) following high dose chemotherapy (HDCT) and stem cell rescue (SCR) for responsive metastatic breast cancer
21. Multicentric phase III study in first line treatment of advanced metastatic breast cancer (ABO). Epirubicin/paclitaxel (ET) vs epirubicin/cyclophosphamide (EC)
22. Her2 overexpression and paclitaxel sensitivity in breast cancer: Therapeutic implications
23. Predictive value of topoisomerase II and other prognostic factors for epirubicin chemotherapy in advanced breast cancer
24. Role of erbB2 in breast cancer chemosensitivity
25. Final report: Weekly (W) herceptin (H) and taxol (T) for metastatic breast cancer (MBC): Analysis of efficacy by HER2 immunophenotype (immunohistochemistry [IHC] and gene amplification (fluorescent in situ hybridization)
26. Baseline serum HER2 (sHER2) levels in the pivotal herceptin breast cancer trials: A comparison of 2 ELISA methods
27. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer
28. The neu-oncoene product in serum and tissue of patients with breast carcinoma
29. C-erbB-2 oncoprotein, CEA, and CA 15-3 in patients with breast cancer: Prognostic value
30. HER-2/neu (c-erB-2) gene and protein in breast cancer
31. c-erbB-2/int-2 amplification appears faster in breast cancer patients receiving second-line endocrine treatment
32. Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer
33. The presence of soluble c-erbB-2 in saliva and serum among women with breast carcinoma: A preliminary study
34. A randomized trial of high-dose chemotherapy and autologous stem cell therapy versus standard therapy in women with metastatic breast cancer who have responded to anthracycline or taxane-based induction chemotherapy
35. A prospective randomized comparison of two doses of combination alkylating agents as consolidation after CAF in high risk primary breast cancer involving ten or more axillary lymph nodes: Preliminary results of 9114/NCIC-MA-13
36. Randomized phase III study of high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin in operable breast cancer with 4 or more axillary lymph nodes